Direct oral anticoagulants versus percutaneous left atrial appendage occlusion in atrial fibrillation: 5-year outcomes

LAAO is an emerging option for thromboembolic event prevention in patients with NVAF. We previously reported data on comparison between LAAO and DOAC at two-year follow-up in NVAF patients at HBR (HAS-BLED ≥3). Limited data are available on long term follow-up. We aimed to evaluate the efficacy and...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cardiology 2023-10, Vol.389, p.131188-131188, Article 131188
Main Authors: Melillo, Francesco, Leo, Giulio, Parlati, Antonio L.M., Gaspardone, Carlo, Bellini, Barbara, Della Bella, Paolo, Montorfano, Matteo, Mazzone, Patrizio, Nemola, Giulia, Cozzani, Gianmarco, Stella, Stefano, Ancona, Francesco, Ingallina, Giacomo, Salerno, Anna, Cera, Michela, Agricola, Eustachio, Margonato, Alberto, Godino, Cosmo
Format: Article
Language:English
Subjects:
Anticoagulant therapy
Atrial fibrillation
Bleeding risk
Left atrial appendage occlusion
Transcatheter
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:LAAO is an emerging option for thromboembolic event prevention in patients with NVAF. We previously reported data on comparison between LAAO and DOAC at two-year follow-up in NVAF patients at HBR (HAS-BLED ≥3). Limited data are available on long term follow-up. We aimed to evaluate the efficacy and safety of DOACs versus LAAO indication after 5 years. We enrolled 193 HBR treated with LAAO and 189 HBR patients with DOACs. At baseline, LAAO group had higher HAS-BLED (4.2 vs 3.3, p 
ISSN:0167-5273
1874-1754
DOI:10.1016/j.ijcard.2023.131188